Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1441. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. (Abstract)

Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. 8624301 1996 06 26 2016 10 17 0923-7534 6 9 1995 Nov Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. 948-9 Smyth J F JF Department of Clinical Oncology, Western General Hospital, Edinburgh, UK. Hardcastle J D JD Denton G G Alderson D D Grace R H RH Mansi J L JL Yosef H M HM Nordle O O Lauri H H Wählby (...) S S eng Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial England Ann Oncol 9007735 0923-7534 0 Antineoplastic Agents 0 Nitrosourea Compounds 1EQV5MLY3D Taurine 511F69K76Y 1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea U3P01618RT Fluorouracil IM Ann Oncol. 1996 Feb;7(2):211 8777181 Aged Antineoplastic Agents administration & dosage therapeutic use Colorectal Neoplasms drug therapy pathology Female

1996 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

1442. Randomised study of screening for colorectal cancer with faecal-occult-blood test. (Abstract)

Randomised study of screening for colorectal cancer with faecal-occult-blood test. Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOB) tests can lead to a reduction in mortality from colorectal cancer (CRC). The aim of this randomised study was to compare mortality rates after FOB tests every 2 years during a 10-year period with those of unscreened similar controls.140,000 people aged 45-75 years lived in Funen

1996 Lancet Controlled trial quality: uncertain

1443. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. (Abstract)

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. There is growing evidence that faecal-occult-blood (FOB) screening may reduce colorectal cancer (CRC) mortality, but this reduction in CRC mortality has not been shown in an unselected population-based randomised controlled trial. The aim of this study was to assess the effect of FOB screening on CRC mortality in such a setting.Between February, 1981, and January, 1991, 152,850 people aged 45-74 years who lived (...) with those who tested positive but in whom no neoplasia was found on colonoscopy, were invited to take part in further screening every 2 years. Screening was stopped in February, 1995, by which time screening-group participants had been offered FOB tests between three and six times. Screening-group participants who had a positive test were offered full colonoscopy. All participants were followed up until June, 1995. The primary outcome measure was CRC mortality.Of the 152,850 individuals recruited

1996 Lancet Controlled trial quality: predicted high

1444. Follow-up in colorectal cancer patients: a cost-benefit analysis

, Segala M, Capko D, Andreoni B, Tiberio G. Follow-up in colorectal cancer patients: a cost-benefit analysis. Annals of Surgical Oncology 1996; 3(4): 349-357 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Colonic Neoplasms /economics /mortality /surgery; Cost-Benefit Analysis; Humans; Monitoring, Physiologic /economics; Neoplasm Recurrence, Local; Postoperative Care /economics; Rectal Neoplasms /economics /mortality /surgery; Survival Rate AccessionNumber 21996000743 Date bibliographic (...) assessment on the reliability of the study and the conclusions drawn. Health technology Clinical follow-up after curative surgery for colorectal cancer. Type of intervention Treatment and palliative care. Economic study type Cost-effectiveness analysis. Study population Patients who survived curative surgery for stage I-III colorectal adenocarcinoma. The mean age was 65.2 years. Patients with stage IV colorectal adenocarcinoma were excluded from the study. Setting Hospital. The economic study was carried

1996 NHS Economic Evaluation Database.

1445. 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer

5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer Bliss E, Robert G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bliss E, Robert G. 5 (...) -fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996 Authors' objectives The authors examine how worthwhile is the proposal that all patients with Duke's stage C colorectal cancer be offered 5-fluorouracil (5-FU) as adjuvant chemotherapy following surgery. Authors' conclusions There are undoubted benefits, but in view of side effects the cost of QALYs is likely to be at the upper end of the range

1996 Health Technology Assessment (HTA) Database.

1446. Positron emission tomography: systematic review. PET as a diagnostic test in colorectal cancer

emission tomography. Descriptive analysis of experience with PET in VA. A systematic review update of FDG-PET as a diagnostic test in cancer and Alzheimer's disease. Technology Assessment Program. Boston (MA): Veterans Affairs Medical Center, Health Services Research and Development Service; 1998. Report No.: 10. Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Diagnostic Techniques and Procedures; Tomography, Emission-Computed AccessionNumber 11997008387 Date bibliographic (...) provide a range of data on the demographic and clinical characteristics of patients on whom PET studies are performed, and on their clinical outcomes in a variety of settings. The use of PET to avoid unnecessary surgery by detecting unresectable recurrent disease in patients who are scheduled for surgery based on other imaging and blood chemistry studies should be systematically addressed in larger patient samples. If it is demonstrated that post-operative follow-up in colorectal cancer patients

1996 DARE.

1447. Advanced colorectal carcinoma: redefining the role of oral ftorafur

on the reliability of the study and the conclusions drawn. Health technology Oral ftorafur, an in-vivo pro-drug (tetrahydro-2-furanyl derivative of 5-fluorouracil) and a known antineoplastic agent in colorectal cancer. Type of intervention Treatment. Economic study type Cost-effectiveness and cost-utility analyses. Study population The study population comprised elderly patients who had undergone resection of histologically confirmed adenocarcinoma of the large bowel and rectum, who had not yet given (...) ftorafur and leucovorin is at least as effective as, and much less costly than, the current standard IV therapy (5-FU and leucovorin) in terms of providing significant anti-tumour effect, palliation, ease of administration and relatively few side effects. A home treatment programme based on oral ftorafur may be the most desirable option for all patients with advanced colorectal carcinoma. CRD COMMENTARY - Selection of comparators The reason for the choice of comparators is clear. Validity of estimate

1996 NHS Economic Evaluation Database.

1448. Calcium does not protect against colorectal neoplasia

Calcium does not protect against colorectal neoplasia Calcium does not protect against colorectal neoplasia Calcium does not protect against colorectal neoplasia Bergsma-Kadijk J A, van't Veer P, Kampman E, Burema J Authors' objectives To assess whether calcium decreases the risk of colorectal neoplasia by binding bowel-irritating compounds and diminishing mucosal proliferation. Searching MEDLINE was searched from January 1980 to September 1994 with the following keywords: 'site' ('colon (...) ', 'rectum', 'colorectal'), 'endpoint' ('cancer', 'carcinoma', 'tumour', 'polyps', 'hyperproliferation') and 'calcium' ('calcium diet', 'dietary', 'dairy'). Current Contents for 1994 (July to September) and the reference lists of retrieved papers were also examined. Study selection Study designs of evaluations included in the review Cohort and case-control studies were included. Specific interventions included in the review Calcium intake. Participants included in the review Men and women were included

1996 DARE.

1449. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published literature

regional chemotherapy to the liver should be offered to patients with isolated liver metastases after curative resection of colorectal cancer may depend on the cost-effectiveness of the procedure. On present evidence, it appears to improve survival in the short-to-medium term. Bibliographic details Harmantas A, Rotstein L E, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published (...) literature. Cancer 1996; 78(8): 1639-1645 PubMedID Other publications of related interest DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /mortality /pathology; Floxuridine /administration & Fluorouracil /administration & Humans; Infusions, Intra-Arterial; Liver Neoplasms /drug therapy /mortality /secondary; Survival Rate; Treatment Outcome; dosage; dosage AccessionNumber 11996001716

1996 DARE.

1450. Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis

Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis Reid F D, Mercer P M, Harrison M, Bates T Authors' objectives To evaluate whether cholecystectomy is associated with an increased risk of colorectal cancer. Searching A computerised search of MEDLINE was performed in addition to manual searches. Study selection Study designs (...) of evaluations included in the review Case-control studies and cohort studies were included. Specific interventions included in the review Cholecystectomy. Participants included in the review Patients with colorectal cancer and age-sex-matched controls without colorectal cancer were included. Outcomes assessed in the review The number of patients with colorectal cancer was assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected

1996 DARE.

1451. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia

of colorectal cancer was 23 per 1,000 (95% CI: 21 - 26) for the annual screen group and 26per 1,000 (CI: 23 - 28) for the control group; the cumulative mortality results were 5.88 (CI: 4.61 - 7.15) and 8.83 (CI: 7.26 - 10.4) for the annual-screen and control groups respectively. There were four cases of perforation of the colon per 12,246 colonoscopies carried out and 11 incidents of serious bleeding. Clinical conclusions The Minnesota trial showed a 33% reduction in colorectal cancer mortality (...) Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Salkeld G, Young G, Irwig L, Haas M, Glasziou P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

1996 NHS Economic Evaluation Database.

1452. Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system

, sigmoidoscopy and colonoscopy. The surgical technologies for treating the disease were colectomy and hepatic resection. Type of intervention Diagnosis and treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised 12,150 patients with a diagnosis of carcinoma of the colon and rectum, of whom 6,607 were listed with hepatic metastases. Setting The large, nationwide hospital system operated by the US Department of Veterans Affairs (DVA) was the setting (...) . Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. Journal of the American College of Surgeons 1996; 182(4): 353-361 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Carcinoma /economics /secondary /surgery; Colectomy; Colorectal Neoplasms /economics /pathology /surgery; Hospitals, Veterans; Humans; Liver Neoplasms /secondary; Lung Neoplasms /secondary; Medical Records; Retrospective Studies; Survival Analysis; Treatment Outcome

1996 NHS Economic Evaluation Database.

1453. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer

Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adjuvant intraportal chemotherapy in patients with colorectal cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population 252 colorectal cancer patients received adjuvant intraportal chemotherapy and 253 controls with colorectal cancer received no adjuvant chemotherapy. No other information about

1996 NHS Economic Evaluation Database.

1454. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre

for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre. European Journal of Cancer Prevention 1996; 5(1): 49-55 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adenoma /prevention & Adult; Colonic Neoplasms /prevention & Colonoscopy /economics; Cost-Benefit Analysis; Costs and Cost Analysis; Endoscopy; Female; Gastrointestinal Neoplasms /prevention & Gastroscopy /economics; Germany; Humans; Male; Mass Screening /economics /methods; Middle (...) Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre Manus B, Bragelmann R, Armbrecht U, Stolte M, Stockbrugger R W Record Status This is a critical abstract of an economic

1996 NHS Economic Evaluation Database.

1455. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK) (Abstract)

with tumour-involved lymph nodes (Dukes' C; 0.67 [0.45-0.99], p = 0.045) and for those with colon cancer (0.78 [0.56-1.09], p = 0.151). Most of the difference in overall and disease-free survival could be attributed to a consistent reduction of all kinds of tumour recurrences (local relapses, liver metastases, and other distant metastases) in the treated group, rather than to a reduction of liver relapses only. We conclude that part of the benefit obtained with a single course of adjuvant chemotherapy via (...) Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK) The efficacy of adjuvant chemotherapy after surgery for colorectal cancer remains unproven. We have investigated the efficacy of a perioperative intraportal cytotoxic regimen in a randomised trial of 533 patients with operable colorectal carcinoma. Patients were randomly assigned either a single course of portal infusion with mitomycin (10 mg/m2, one

1995 Lancet Controlled trial quality: uncertain

1456. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. (Abstract)

completed the planned treatment. Side-effects were clinically acceptable with only 1 treatment-related death. The commonest side-effects were gastrointestinal, but severe toxic effects (WHO grade 4) occurred in fewer than 3% of cases. We conclude that fluorouracil plus high-dose folinic acid is a well-tolerated and effective 6-month adjuvant regimen for colon cancer. (...) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. The role of fluorouracil and folinic acid and adjuvant therapy for colon cancer is not clear. We undertook independently three randomised trials to find out the efficacy of fluorouracil and high-dose folinic acid after surgery for Dukes' B and C stage colon cancer. The three studies by the Gruppo Interdisciplinare Valutazione Interventi

1995 Lancet Controlled trial quality: uncertain

1457. Screening for colorectal cancer: what are the costs?

Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Weller D, Moss J, Hiller J, Thomas J, Edwards J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The fecal occult blood test (FOBT) as a method for screening for the detection of colorectal cancer. Type of intervention Screening. Economic study type Cost-effectiveness study. Study population Patients screened for colorectal cancer. Setting The practice setting is the community with follow up in general practice and institutions as required. The study was undertaken in South Australia. Dates to which data relate Effectiveness and resource data were collected

1995 NHS Economic Evaluation Database.

1458. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies

analysed separately, RRs of ORT and colorectal cancer were not significant. Cost information No Authors' conclusions There is no evidence that ORT use influences the risk of colon or rectal cancer. It was not possible to analyse the effect of concomitant progestogens or length of therapy on cancer risk, since the necessary information was not given in most of the studies. The overall RR of 0.92 does not definitively prove there is no association between ORT use and colorectal cancer, but it is the best (...) estimate from all currently published studies. These findings are contrary to the suggestion in some review articles that ORT may reduce the risk of colorectal cancer. CRD commentary This appears to be an appropriate use of meta-analysis. Implications of the review for practice and research The use of non-contraceptive oestrogen replacement therapy does not appear to affect the risk of cancer of the colon or rectum. Funding The Anti-Cancer Foundation of South Australia. Bibliographic details MacLennan

1995 DARE.

1459. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation

Prev 1991;1(Suppl 2):21. Thomas W M, Pye G, Hardcastle J, et al. Faecal occult blood screening for colorectal neoplasia: a randomised trial of three days or six days of tests. Br J Surg 1990;7(3):277-9. Indexing Status Subject indexing assigned by NLM MeSH Adenomatous Polyps /diagnosis /surgery; Adolescent; Adult; Aerospace Medicine; Colonic Polyps /diagnosis /surgery; Colorectal Neoplasms /diagnosis /epidemiology /prevention & Cost-Benefit Analysis; Female; Great Britain; Humans; Incidence; Male (...) Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation Daniels K, McKee M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

1995 NHS Economic Evaluation Database.

1460. Cost-effectiveness of screening for colorectal cancer: a simulation model

Cost-effectiveness of screening for colorectal cancer: a simulation model Cost-effectiveness of screening for colorectal cancer: a simulation model Cost-effectiveness of screening for colorectal cancer: a simulation model Neilson A R, Whynes D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening for colorectal cancer using faecal occult blood (FOB) test and/or flexible sigmoidoscopy. Type of intervention Screening. Economic study type Cost-utility analysis. Study population A cohort of hypothetical subjects between 40 and 90 years of age. Setting Hospital. The economic study was carried out in the United Kingdom. Dates to which data relate The data related to the effectiveness analysis were extracted from clinical

1995 NHS Economic Evaluation Database.